LOS ANGELES, CA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)EPIDERMOLYSIS BULLOSA MEDICAL RESEARCH FOUNDATION, founded in 1990, is a small nonprofit that reported $889K in total revenue in fiscal year 2023. Revenue fell 34% from the prior year — a significant decline worth monitoring. The organization ran a surplus of $488K, a strong 55% operating margin.
THE PRIMARY PURPOSE OF THE ORGANIZATION IS TO FUND MEDICAL RESEARCH TO FIND A CURE FOR EPIDERMOLYSIS BULLOSA. EPIDERMOLYSIS BULLOSA MEDICAL RESEARCH FOUNDATION FUNDS VARIOUS RESEARCH ORGANIZATIONS ACROSS THE UNITED STATES & INTERNATIONALLY FOR CHILDREN'S HEALTH.
THE EBMRF IS DEDICATED TO FINDING A CURE FOR EPIDERMOLYSIS BULLOSA BY FUNDING THE BEST CUTTING EDGE AND INNOVATIVE RESEARCH AND SEEKING OUT NEW RESEARCHERS AND SCIENTISTS AT AMERICA'S TOP...
THE EBMRF IS DEDICATED TO FINDING A CURE FOR EPIDERMOLYSIS BULLOSA BY FUNDING THE BEST CUTTING EDGE AND INNOVATIVE RESEARCH AND SEEKING OUT NEW RESEARCHERS AND SCIENTISTS AT AMERICA'S TOP INSTITUTIONS. THROUGH OUR ONGOING JOINT FUNDING WITH EB RESEARCH PARTNERSHIP OF INDIVIDUAL RESEARCH STUDIES AND CLINICAL TRIALS AT ACCLAIMED UNIVERSITIES, 21 EB CLINICAL RESEARCH CONSORTIUM (EBCRC) SITES AND THROUGH OUR ANNUAL FUNDRAISERS, WE ARE COMMITTED TO FUNDING A CURE AND SUCCESSFUL TREATMENTS FOR EB. GRANTS ARE EVALUATED AND ONCE APPROVED, ARE FUNDED ON A 1 YEAR BASIS, AND ARE SUBJECT TO PROJECT MILESTONES. MULTI-YEAR GRANTS ARE REVIEWED ANNUALLY AND EVALUATED ON THEIR PROGRESS AND OUR AVAILABLE FUNDING. ALL GRANTS INCLUDE A 5% LIMIT ON INDIRECT COSTS.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | $888,776 | $1,354,120 | -0.3% |
| Expenses | $400,692 | $345,807 | +0.2% |
| Net Income | $488,084 | $1,008,313 | -0.5% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| ANDREA PETT-JOSEPH | PRESIDENT/EXECUTIVE DIRECTOR | 5.00 |
Officer
Director
|
$0 | $0 | $0 |
| PAUL JOSEPH | CHIEF FINANCIAL OFFICER | 4.00 |
Officer
Director
|
$0 | $0 | $0 |
| MARC GURVITZ | DIRECTOR | 3.00 |
Director
|
$0 | $0 | $0 |
| PERSIA FARDAD-FINN | DIRECTOR | 4.00 |
Director
|
$0 | $0 | $0 |
| LYNN ANDERSON | FOUNDER, PRESIDENT EMERITUS | 1.00 |
Director
|
$0 | $0 | $0 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2025 | No data | No data | No data | No data |
| 2024 | $888,776 | $400,692 | $4,182,723 | $488,084 |
| 2023 | $1,354,120 | $345,807 | $3,859,639 | $1,008,313 |
| 2022 | $389,920 | $225,491 | $3,800,076 | $164,429 |
| 2021 | $772,726 | $1,497,871 | $3,863,477 | $-725,145 |
| 2020 | $1,472,350 | $1,109,360 | $4,614,354 | $362,990 |
| 2019 | $2,502,866 | $2,928,321 | $2,958,091 | $-425,455 |
| 2018 | $1,025,388 | $2,438,522 | $7,383,602 | $-1,413,134 |
Compare EPIDERMOLYSIS BULLOSA MEDICAL RESEARCH FOUNDATION with other nonprofits in California and across the country.